dc.contributor.author |
Cillóniz, C. |
|
dc.contributor.author |
Dominedò, C. |
|
dc.contributor.author |
Pericàs, J.M. |
|
dc.contributor.author |
Rodriguez-Hurtado, D. |
|
dc.contributor.author |
Torres, A. |
|
dc.date.accessioned |
2020-07-14T00:01:03Z |
|
dc.date.available |
2020-07-14T00:01:03Z |
|
dc.date.issued |
2020 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/8264 |
|
dc.description.abstract |
Very old (aged ≥80 years) adults constitute an increasing proportion of the global population. Currently, this subgroup of patients represents an important percentage of patients admitted to the intensive care unit. Community-acquired pneumonia (CAP) frequently affects very old adults. However, there are no specific recommendations for the management of critically ill very old CAP patients. Multiple morbidities, polypharmacy, immunosenescence and frailty contribute to an increased risk of pneumonia in this population. CAP in critically ill very old patients is associated with higher short-and long-term mortality; however, because of its uncommon presentation, diagnosis can be very difficult. Management of critically ill very old CAP patients should be guided by their baseline characteristics, clinical presentation and risk factors for multidrug-resistant pathogens. Hospitalisation in intermediate care may be a good option for critical ill very old CAP patients who do not require invasive procedures and for whom intensive care is questionable in terms of benefit. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
European Respiratory Society |
|
dc.relation.ispartofseries |
European Respiratory Review |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
mortality |
en_US |
dc.subject |
aged |
en_US |
dc.subject |
human |
en_US |
dc.subject |
incidence |
en_US |
dc.subject |
risk factor |
en_US |
dc.subject |
Acinetobacter |
en_US |
dc.subject |
amoxicillin |
en_US |
dc.subject |
amoxicillin plus clavulanic acid |
en_US |
dc.subject |
antibody response |
en_US |
dc.subject |
B lymphocyte |
en_US |
dc.subject |
cellular immunity |
en_US |
dc.subject |
cephalosporin |
en_US |
dc.subject |
chemokine |
en_US |
dc.subject |
ciprofloxacin |
en_US |
dc.subject |
clarithromycin |
en_US |
dc.subject |
clinical feature |
en_US |
dc.subject |
community acquired pneumonia |
en_US |
dc.subject |
comorbidity |
en_US |
dc.subject |
corticosteroid |
en_US |
dc.subject |
coughing |
en_US |
dc.subject |
critically ill patient |
en_US |
dc.subject |
cytokine |
en_US |
dc.subject |
decision making |
en_US |
dc.subject |
doxycycline |
en_US |
dc.subject |
Escherichia coli |
en_US |
dc.subject |
fever |
en_US |
dc.subject |
frailty |
en_US |
dc.subject |
hospitalization |
en_US |
dc.subject |
humoral immunity |
en_US |
dc.subject |
immunoglobulin A |
en_US |
dc.subject |
immunoglobulin G |
en_US |
dc.subject |
immunosenescence |
en_US |
dc.subject |
inflammation |
en_US |
dc.subject |
intensive care unit |
en_US |
dc.subject |
Klebsiella pneumoniae |
en_US |
dc.subject |
levofloxacin |
en_US |
dc.subject |
long term care |
en_US |
dc.subject |
lower respiratory tract infection |
en_US |
dc.subject |
macrophage |
en_US |
dc.subject |
morbidity |
en_US |
dc.subject |
moxifloxacin |
en_US |
dc.subject |
natural killer cell |
en_US |
dc.subject |
neutrophil |
en_US |
dc.subject |
penicillin G |
en_US |
dc.subject |
polypharmacy |
en_US |
dc.subject |
public health |
en_US |
dc.subject |
quality of life |
en_US |
dc.subject |
Review |
en_US |
dc.subject |
Streptococcus pneumoniae |
en_US |
dc.subject |
thorax pain |
en_US |
dc.subject |
treatment failure |
en_US |
dc.subject |
very elderly |
en_US |
dc.title |
Community-acquired pneumonia in critically ill very old patients: A growing problem |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1183/16000617.0126-2019 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.02.07 |
|
dc.relation.issn |
1600-0617 |
|